KeyCorp Increases Evolent Health (EVH) Price Target to $24.00
Evolent Health (NYSE:EVH) had its price objective hoisted by stock analysts at KeyCorp from $19.00 to $24.00 in a research report issued to clients and investors on Wednesday. The firm presently has an “overweight” rating on the technology company’s stock. KeyCorp’s target price indicates a potential upside of 17.36% from the company’s current price.
Several other equities research analysts have also issued reports on EVH. Jefferies Group set a $22.00 target price on shares of Evolent Health and gave the stock a “buy” rating in a report on Tuesday, February 13th. Wells Fargo & Co decreased their price objective on shares of Evolent Health from $27.00 to $20.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Canaccord Genuity decreased their price objective on shares of Evolent Health from $27.00 to $24.00 and set a “buy” rating for the company in a report on Wednesday, February 28th. Zacks Investment Research lowered shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Thursday, March 8th. Finally, ValuEngine lowered shares of Evolent Health from a “sell” rating to a “strong sell” rating in a report on Monday, April 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $25.00.
Evolent Health opened at $20.45 on Wednesday, Marketbeat.com reports. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.12. Evolent Health has a 12-month low of $10.30 and a 12-month high of $27.50.
In other Evolent Health news, General Counsel Jonathan Weinberg sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, May 22nd. The shares were sold at an average price of $20.02, for a total transaction of $300,300.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Seth Blackley sold 64,398 shares of the firm’s stock in a transaction dated Thursday, May 10th. The shares were sold at an average price of $17.63, for a total transaction of $1,135,336.74. The disclosure for this sale can be found here. Insiders have sold a total of 181,660 shares of company stock valued at $3,220,770 in the last quarter. 4.82% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC purchased a new position in Evolent Health during the 4th quarter valued at about $144,000. Quantbot Technologies LP increased its position in Evolent Health by 111.4% during the 1st quarter. Quantbot Technologies LP now owns 10,815 shares of the technology company’s stock valued at $154,000 after purchasing an additional 5,698 shares during the period. Virtu Financial LLC purchased a new position in Evolent Health during the 4th quarter valued at about $172,000. Fox Run Management L.L.C. purchased a new position in Evolent Health during the 4th quarter valued at about $175,000. Finally, LPL Financial LLC purchased a new position in Evolent Health during the 1st quarter valued at about $184,000.
About Evolent Health
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.